US · LNSR · MEDICAL - EQUIPMENT & SERVICES
LENSAR Inc (LNSR) intrinsic value and stock valuation
$4.46as of 2026-11-21 · Mkt cap 71.6M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
LENSAR Inc DCF and intrinsic value
InvestorsCraft values LNSR with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from LNSR’s statements →
LENSAR Inc Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2018–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Anteris Technologies Global Corp. (AVR) $4.99
- Anika Therapeutics, Inc. (ANIK) $13.23
- Profound Medical Corp. (PROF) $6.38
- TriSalus Life Sciences, Inc. (TLSI) $2.32
- Corbus Pharmaceuticals Holdings, Inc. (CRBP) $2.06
- MaxCyte, Inc. (MXCT) $1.37
- Owlet, Inc. (OWLT) $2.93
- Rapid Micro Biosystems, Inc. (RPID) $0.74
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $58.4M | $53.5M | $42.2M | $35.4M | $34.5M |
| Operating income | -$-24.58M | -$-10.66M | -$-12.23M | -$-20.18M | -$-19.65M |
| Net income | -$-34.28M | -$-31.4M | -$-14.38M | -$-19.91M | -$-19.6M |
| EPSd | -$-2.87M | -$-2.73M | -$-1.31M | -$-1.96M | -$-2.09M |
| Operating cash flow | -$-14.83M | -$-2.27M | -$-9.66M | -$-14.86M | -$-8.97M |
| Capital expenditure | -$-80K | -$-160K | -$-240K | -$-120K | -$-350K |
| Free cash flow | -$-14.91M | -$-2.43M | -$-9.89M | -$-14.97M | -$-9.32M |
| Total assets | $71.4M | $66.3M | $69.6M | $55.8M | $66.5M |
| Total debt | $2.73M | $2.61M | $2.31M | $2.8M | $3.31M |
| Net debt | -$-10.24M | -$-13.65M | -$-18.31M | -$-11.87M | -$-28.32M |
| Total equity | -$-26.02M | $18.7M | $47.2M | $42M | $54.9M |
| Cash and short-term investments | $18M | $22.5M | $24.1M | $14.7M | $31.6M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $58.4M | $53.5M | $42.2M | $35.4M | $34.5M |
| Cost of revenue | $31.3M | $27.6M | $21.1M | $15.4M | $16.6M |
| Gross profit | $27.1M | $25.9M | $21.1M | $20M | $17.8M |
| Research and development expenses | $5.62M | $5.33M | $6.14M | $11.8M | $12.4M |
| Selling, general and administrative expenses | $45.2M | $26.5M | $26.1M | $27.2M | $23.9M |
| Other expenses | $920K | $4.7M | $1.1M | $1.15M | $1.24M |
| Operating expenses | $51.7M | $36.5M | $33.3M | $40.1M | $37.5M |
| Cost and expenses | $83M | $64.2M | $54.4M | $55.5M | $54.1M |
| Interest income | $90K | $100K | $90K | $20K | $30K |
| Interest expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation and amortization | $4.5M | $3.93M | $3.52M | $3.41M | $2.76M |
| Ebitda | -$-29.78M | -$-3M | -$-10.87M | -$-16.51M | -$-16.84M |
| Operating income | -$-24.58M | -$-10.66M | -$-12.23M | -$-20.18M | -$-19.65M |
| Total other income/expenses, net | -$-9.7M | -$-20.74M | -$-2.15M | $260K | $50K |
| Income before tax | -$-34.28M | -$-31.4M | -$-14.38M | -$-19.91M | -$-19.6M |
| Income tax expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$-34.28M | -$-31.4M | -$-14.38M | -$-19.91M | -$-19.6M |
| Weighted average shares outstanding | $12M | $11.5M | $11M | $10.2M | $9.37M |
| Weighted average diluted shares outstanding | $12M | $11.5M | $11M | $10.2M | $9.37M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $18M | $22.5M | $24.1M | $14.7M | $31.6M |
| Net receivables | $6.38M | $6.48M | $4.32M | $6.24M | $4.99M |
| Inventory | $21.5M | $11.4M | $15.7M | $11.7M | $6.49M |
| Total current assets | $46.8M | $42M | $46.4M | $33.7M | $44.8M |
| Property, plant and equipment, net | $510K | $660K | $10.3M | $6.88M | $7.45M |
| Goodwill and intangible assets | $5.19M | $6.11M | $11M | $12.1M | $10.9M |
| Long-term investments | $0.00 | $1.16M | $490K | $440K | $0.00 |
| Total non-current assets | $24.7M | $24.3M | $23.1M | $22.1M | $21.7M |
| Total assets | $71.4M | $66.3M | $69.6M | $55.8M | $66.5M |
| Accounts payable | $19M | $6M | $4.01M | $5.42M | $2.69M |
| Short-term debt | $750K | $520K | $560K | $530K | $510K |
| Deferred revenue | $3.07M | $1.68M | $1.35M | $770K | $900K |
| Total current liabilities | $40.6M | $15M | $11.6M | $11.4M | $8.71M |
| Long-term debt | $1.99M | $2.09M | $1.75M | $2.27M | $2.8M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $56.9M | $32.7M | $10.8M | $2.44M | $2.87M |
| Capital lease obligations | $2.73M | $2.61M | $2.31M | $2.8M | $3.31M |
| Total liabilities | $97.5M | $47.7M | $22.4M | $13.9M | $11.6M |
| Common stock | $120K | $120K | $110K | $110K | $110K |
| Retained earnings | -$-177.57M | -$-143.29M | -$-111.89M | -$-97.51M | -$-77.59M |
| Accumulated other comprehensive income (loss) | $0.00 | $10K | $0.00 | $0.00 | $0.00 |
| Total equity | -$-26.02M | $18.7M | $47.2M | $42M | $54.9M |
| Total investments | $5M | $7.35M | $3.94M | $440K | $0.00 |
| Total debt | $2.73M | $2.61M | $2.31M | $2.8M | $3.31M |
| Net debt | -$-10.24M | -$-13.65M | -$-18.31M | -$-11.87M | -$-28.32M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-34.28M | -$-31.4M | -$-14.38M | -$-19.91M | -$-19.6M |
| Depreciation and amortization | $4.5M | $3.93M | $3.52M | $3.41M | $2.76M |
| Stock-based compensation | $3.14M | $2.67M | $5.54M | $6.61M | $6.87M |
| Change in working capital | $1.1M | -$-3.04M | -$-7.78M | -$-5.58M | -$-40K |
| Accounts receivable | $290K | -$-2.1M | $1.08M | -$-1.44M | -$-2.65M |
| Inventory | -$-13.9M | -$-4.9M | -$-7.46M | -$-6.89M | $2.33M |
| Accounts payable | $13M | $1.96M | -$-1.42M | $2.73M | $210K |
| Net cash provided by operating activities | -$-14.83M | -$-2.27M | -$-9.66M | -$-14.86M | -$-8.97M |
| Investments in property, plant and equipment | -$-80K | -$-160K | -$-240K | -$-120K | -$-350K |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for investing activities | $1.28M | -$-2.16M | -$-4.16M | -$-120K | -$-350K |
| Common stock issued | $260K | $60K | $5.88M | $410K | $360K |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $10.3M | $80K | $19.8M | -$-1.99M | $360K |
| Net change in cash | -$-3.29M | -$-4.36M | $5.95M | -$-16.96M | -$-8.96M |
| Cash at end of period | $13M | $16.3M | $20.6M | $14.7M | $31.6M |
| Operating cash flow | -$-14.83M | -$-2.27M | -$-9.66M | -$-14.86M | -$-8.97M |
| Capital expenditure | -$-80K | -$-160K | -$-240K | -$-120K | -$-350K |
| Free cash flow | -$-14.91M | -$-2.43M | -$-9.89M | -$-14.97M | -$-9.32M |
Line items
Line items
Line items
About LENSAR Inc
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser systems for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System, Europe, Asia, South Korea, and internationally. The company offers the LENSAR Laser System, which incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes by providing imaging, procedure planning, design, and precision. It also provides ALLY Robotic Cataract Laser System, a compact cataract treatment system that is designed to allow surgeons to perform sterile laser-assisted cataract surgery in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.
- CEO
- Nicholas T. Curtis
- Employees
- 150
- Beta
- 0.87
Explore
Frequently asked questions
What is the intrinsic value of LENSAR Inc (LNSR)?
LENSAR Inc (LNSR) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is LNSR undervalued?
LNSR trades at a price of $4.46 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.